Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost “IOP homeostasis ? Why most people do not ever develop glaucoma” has been added to your cart. View cart €15.00 Clinical safety and efficacy of the first-in-class Rho kinase inhibitor for lowering IOP: netarsudil and the fixed-dose combination of netarsudil and latanoprost quantity Add to cart Category: Articles Tag: Volume 3 Description Description Authors: Janet B. Serle, Jake Radell Related products Intraocular pressure control through linked trabecular meshwork and collector channel motion €15.00 Add to cart Dynamic mechanobiology of conventional outflow €15.00 Add to cart Biomarkers in primary open-angle glaucoma €15.00 Add to cart Autophagy in outflow pathway physiology and pathophysiology €15.00 Add to cart